| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1177/154411130301400505 |
| P8608 | Fatcat ID | release_lu6dfplnyrfevph3ecahjdaakm |
| P953 | full work available at URL | http://cro.sagepub.com/content/14/5/345.full.pdf |
| http://journals.sagepub.com/doi/full-xml/10.1177/154411130301400505 | ||
| http://journals.sagepub.com/doi/pdf/10.1177/154411130301400505 | ||
| P698 | PubMed publication ID | 14530303 |
| P5875 | ResearchGate publication ID | 9062813 |
| P2093 | author name string | T-C Wu | |
| Kalpana Devaraj | |||
| Maura L. Gillison | |||
| P2860 | cites work | Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells | Q43983069 |
| Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. | Q44139432 | ||
| A controlled trial of a human papillomavirus type 16 vaccine | Q44366335 | ||
| Genital papillomavirus infection and cervical dysplasia--opportunistic complications of HIV infection | Q44485504 | ||
| Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells | Q44565801 | ||
| Immunisation of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen | Q44761763 | ||
| Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response | Q45197386 | ||
| Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector | Q45734168 | ||
| Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro | Q45737453 | ||
| Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice | Q45739070 | ||
| Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast | Q45759645 | ||
| A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. | Q45769906 | ||
| Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation | Q45771837 | ||
| Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe | Q45784453 | ||
| Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies | Q45789488 | ||
| In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine | Q45844272 | ||
| The increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression | Q45853259 | ||
| Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. | Q45978807 | ||
| Changing patterns of tonsillar squamous cell carcinoma in the United States | Q46475604 | ||
| Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world | Q47877336 | ||
| Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs | Q48561706 | ||
| Oral somatic transgene vaccination using attenuated S. typhimurium | Q50132575 | ||
| Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains | Q50137651 | ||
| Risk factors for juvenile onset recurrent respiratory papillomatosis. | Q50631475 | ||
| Sites of predilection in recurrent respiratory papillomatosis. | Q51140793 | ||
| Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. | Q52020790 | ||
| Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck | Q43571689 | ||
| Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells | Q43623624 | ||
| Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study | Q43678940 | ||
| Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma | Q43732858 | ||
| Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization | Q24655648 | ||
| Gene vaccination with naked plasmid DNA: mechanism of CTL priming | Q24676957 | ||
| Cancer therapy using a self-replicating RNA vaccine | Q27481056 | ||
| Papillomaviruses and cancer: from basic studies to clinical application | Q29614745 | ||
| Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor | Q29619247 | ||
| Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine | Q31961522 | ||
| Evidence for a causal association between human papillomavirus and a subset of head and neck cancers | Q33180284 | ||
| Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. | Q33559590 | ||
| Papillomavirus-like particle vaccines for cervical cancer | Q33632759 | ||
| Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease? | Q33635781 | ||
| Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas | Q33707499 | ||
| Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens | Q33714644 | ||
| Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine | Q33780088 | ||
| Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions | Q33784891 | ||
| Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer | Q33800432 | ||
| Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6 | Q33816200 | ||
| Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. | Q33840918 | ||
| Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site | Q33846428 | ||
| Immunization with a pentameric L1 fusion protein protects against papillomavirus infection | Q33853398 | ||
| Human papillomavirus vaccines | Q33860427 | ||
| Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus--rabbit model | Q33874465 | ||
| Structure-function analysis of the human papillomavirus type 16 E7 oncoprotein | Q33932831 | ||
| DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector | Q34069023 | ||
| Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. | Q34189203 | ||
| Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers | Q34221597 | ||
| Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens | Q34291693 | ||
| Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group | Q34313864 | ||
| Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen | Q34332858 | ||
| Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines | Q34342818 | ||
| Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. | Q34416048 | ||
| Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. | Q34505761 | ||
| Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome | Q34510917 | ||
| Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors | Q35134462 | ||
| Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit | Q35482140 | ||
| A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants. | Q54607806 | ||
| Dendritic Cells as Carriers for a Cytotoxic T-Lymphocyte Epitope-Based Peptide Vaccine in Protection Against a Human Papillomavirus Type 16-Induced Tumor | Q56795686 | ||
| Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus | Q56797784 | ||
| Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production | Q56959381 | ||
| Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A | Q64382778 | ||
| The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes | Q67686616 | ||
| Regression phenomenon of numerous flat warts--an experiment on the nature of tumor immunity in man | Q70184772 | ||
| Prophylactic and therapeutic vaccination against a mucosal papillomavirus | Q70459386 | ||
| Prevalence of mucosotropic human papillomaviruses in squamous-cell carcinoma of the head and neck | Q71091023 | ||
| Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity | Q71563753 | ||
| Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16 | Q71596317 | ||
| DNA-based immunization by in vivo transfection of dendritic cells | Q71607054 | ||
| A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours | Q71803282 | ||
| Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial | Q73112587 | ||
| Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors | Q73235473 | ||
| Human papillomavirus in head and neck squamous cell carcinomas in nonsmokers | Q73353865 | ||
| Therapeutic potential of protein and adjuvant vaccinations on tumour growth | Q73636790 | ||
| Viral recombinant vaccines to the E6 and E7 antigens of HPV-16 | Q73693192 | ||
| Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes | Q73740013 | ||
| DNA vaccines | Q73779250 | ||
| Antigen-specific immunotherapy for human papillomavirus 16 E7-expressing tumors grown in the liver | Q74034489 | ||
| Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization | Q74128255 | ||
| Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif | Q74165203 | ||
| DNA packaging by L1 and L2 capsid proteins of bovine papillomavirus type 1 | Q74500657 | ||
| Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX | Q74562997 | ||
| Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts | Q74607911 | ||
| Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein | Q77180605 | ||
| Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination | Q77747836 | ||
| Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts | Q78024457 | ||
| DNA vaccines | Q93896322 | ||
| Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas | Q35830690 | ||
| Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. | Q35840539 | ||
| Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model | Q35891225 | ||
| Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen | Q36167792 | ||
| DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1 | Q36234063 | ||
| Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx | Q36311277 | ||
| Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells | Q36354420 | ||
| Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells | Q36357544 | ||
| CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity | Q36380885 | ||
| Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. | Q36401759 | ||
| Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses | Q37009584 | ||
| Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies | Q38304498 | ||
| Human papillomavirus (HPV) type 16 and 33 E6/E7 region transcripts in tonsillar carcinomas can originate from integrated and episomal HPV DNA | Q39100082 | ||
| Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas | Q39121493 | ||
| In vitro gene transfer using human papillomavirus-like particles | Q39723134 | ||
| Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes | Q40064324 | ||
| Heat shock protein-peptide complexes in cancer immunotherapy | Q40573301 | ||
| Immunology of the human papilloma virus in relation to cancer | Q40573316 | ||
| Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens | Q40703649 | ||
| Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. | Q40747474 | ||
| Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors im | Q40767663 | ||
| A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. | Q40792027 | ||
| Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. | Q40807324 | ||
| Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen | Q40811128 | ||
| Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen. | Q40811213 | ||
| Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine | Q40811278 | ||
| Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments | Q40827568 | ||
| Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. | Q40838459 | ||
| Marek's disease virus (MDV) homologues of herpes simplex virus type 1 UL49 (VP22) and UL48 (VP16) genes: high-level expression and characterization of MDV-1 VP22 and VP16. | Q40860189 | ||
| Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7. | Q40863595 | ||
| Assembly of human papillomavirus type 16 pseudovirions in Saccharomyces cerevisiae | Q40876531 | ||
| Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine | Q40882233 | ||
| Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. | Q40889921 | ||
| Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 | ||
| Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection | Q40948891 | ||
| Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity | Q40959565 | ||
| Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope | Q40996268 | ||
| Synthetic peptides of human papillomavirus type 18 E6 harboring HLA-A2.1 motif can induce peptide-specific cytotoxic T-cells from peripheral blood mononuclear cells of healthy donors | Q41026563 | ||
| Enhancing immune responses using suicidal DNA vaccines. | Q41034921 | ||
| Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector. | Q41056892 | ||
| Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs | Q41057373 | ||
| Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. | Q41068616 | ||
| Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo | Q41071177 | ||
| Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo | Q41079157 | ||
| Intercellular trafficking and protein delivery by a herpesvirus structural protein | Q41133058 | ||
| Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization | Q41203441 | ||
| Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines | Q41415648 | ||
| Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells | Q41532466 | ||
| Nucleic acid vaccines: an overview | Q41542908 | ||
| Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma | Q41559182 | ||
| Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 | Q41589138 | ||
| Human papillomavirus type 16 immortalized cervical keratinocytes contain transcripts encoding E6, E7, and E2 initiated at the P97 promoter and express high levels of E7 | Q41668529 | ||
| Structure and transcription of human papillomavirus sequences in cervical carcinoma cells | Q41914039 | ||
| Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. | Q42621598 | ||
| Sindbis virus: an efficient, broad host range vector for gene expression in animal cells | Q42991441 | ||
| Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. | Q43440882 | ||
| Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. | Q43514345 | ||
| Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins | Q43562400 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | HPV vaccine | Q900189 |
| P304 | page(s) | 345-362 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Journal of Dental Research | Q6295082 |
| Critical Reviews in Oral Biology and Medicine | Q45134405 | ||
| P1476 | title | Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma | |
| Development of HPV Vaccines for HPV-associated Head and Neck Squamous Cell Carcinoma | |||
| P478 | volume | 14 |
| Q34121681 | A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers |
| Q45888118 | A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers. |
| Q38838178 | An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression |
| Q34367405 | Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites |
| Q35647100 | Does pretreatment seropositivity to human papillomavirus have prognostic significance for head and neck cancers? |
| Q35234948 | Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. |
| Q37123825 | Head and neck cancer immunotherapy: clinical evaluation |
| Q33280921 | Human papilloma virus in squamous carcinoma of the head and neck: a study of cases in south east Scotland |
| Q40252793 | Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7. |
| Q40423103 | Immunity to squamous carcinoma in mice immunized with dendritic cells transfected with genomic DNA from squamous carcinoma cells |
| Q39955461 | Immunotherapy of head and neck cancer: current and future considerations |
| Q36097148 | Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein |
| Q34518716 | Molecular biology of squamous cell carcinoma of the head and neck |
| Q36988805 | Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment |
| Q37762309 | Oncogenic impact of human papilloma virus in head and neck cancer |
| Q26744446 | Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies |
| Q36083415 | Presence and influence of human papillomaviruses (HPV) in Tonsillar cancer |
| Q36652548 | Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical Cancers |
| Q26782255 | Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer |
| Q36528685 | Role of human papillomavirus in the etiology of head and neck cancer |
| Q34475726 | T cell-tumor interaction directs the development of immunotherapies in head and neck cancer |
| Q26765429 | Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC) |
| Q37970005 | The clinical implications of antitumor immunity in head and neck cancer |
| Q36409233 | The role of human papillomavirus in squamous carcinoma of the head and neck |
| Q56937332 | Therapeutic human papillomavirus vaccines: current clinical trials and future directions |
Search more.